Literature DB >> 25827529

Mucosal vaccination by adenoviruses displaying reovirus sigma 1.

Eric A Weaver1, Zenaido T Camacho2, Matthew L Hillestad3, Catherine M Crosby4, Mallory A Turner4, Adam J Guenzel4, Hind J Fadel4, George T Mercier5, Michael A Barry6.   

Abstract

We developed adenovirus serotype 5 (Ad5) vectors displaying the sigma 1 protein from reovirus as mucosal vaccines. Ad5-sigma retargets to JAM-1 and sialic acid, but has 40-fold reduced gene delivery when compared to Ad5. While weaker at transduction, Ad5-sigma generates stronger T cell responses than Ad5 when used for mucosal immunization. In this work, new Ad5-fiber-sigma vectors were generated by varying the number of fiber β-spiral shaft repeats (R) between the fiber tail and sigma. Increasing chimera length led to decreasing insertion of these proteinsAd5 virions. Ad-R3 and R14 vectors effectively targeted JAM-1 in vitro while R20 did not. When wereused to immunize mice by the intranasal route, Ad5-R3-sigma produced higher serum and vaginal antibody responses than Ad5. These data suggest optimized Ad-sigma vectors may be useful vectors for mucosal vaccination.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenovirus; Immunization; Mucosal; Reovirus; Sigma 1

Mesh:

Substances:

Year:  2015        PMID: 25827529      PMCID: PMC4461457          DOI: 10.1016/j.virol.2015.02.050

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

Review 1.  Virus yoga: the role of flexibility in virus host cell recognition.

Authors:  Eugene Wu; Glen R Nemerow
Journal:  Trends Microbiol       Date:  2004-04       Impact factor: 17.079

2.  A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1.

Authors:  George T Mercier; Jacquelyn A Campbell; James D Chappell; Thilo Stehle; Terence S Dermody; Michael A Barry
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

3.  Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells.

Authors:  D J Von Seggern; S Huang; S K Fleck; S C Stevenson; G R Nemerow
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Hum Gene Ther       Date:  2004-11       Impact factor: 5.695

5.  Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber.

Authors:  V Legrand; D Spehner; Y Schlesinger; N Settelen; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection.

Authors:  J Zabner; P Freimuth; A Puga; A Fabrega; M J Welsh
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

7.  Structure-function analysis of reovirus binding to junctional adhesion molecule 1. Implications for the mechanism of reovirus attachment.

Authors:  J Craig Forrest; Jacquelyn A Campbell; Pierre Schelling; Thilo Stehle; Terence S Dermody
Journal:  J Biol Chem       Date:  2003-09-09       Impact factor: 5.157

8.  Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification.

Authors:  M Brandon Parrott; Kristen E Adams; George T Mercier; Hoyin Mok; Samuel K Campos; Michael A Barry
Journal:  Mol Ther       Date:  2003-10       Impact factor: 11.454

9.  Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans.

Authors:  B R Grubb; R J Pickles; H Ye; J R Yankaskas; R N Vick; J F Engelhardt; J M Wilson; L G Johnson; R C Boucher
Journal:  Nature       Date:  1994-10-27       Impact factor: 49.962

10.  Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee.

Authors:  Jennifer H Tai; John V Williams; Kathryn M Edwards; Peter F Wright; James E Crowe; Terence S Dermody
Journal:  J Infect Dis       Date:  2005-03-08       Impact factor: 5.226

View more
  1 in total

1.  Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.

Authors:  Meera Madhavan; Adam J Ritchie; Jeremy Aboagye; Daniel Jenkin; Samuel Provstgaad-Morys; Iona Tarbet; Danielle Woods; Sophie Davies; Megan Baker; Abigail Platt; Amy Flaxman; Holly Smith; Sandra Belij-Rammerstorfer; Deidre Wilkins; Elizabeth J Kelly; Tonya Villafana; Justin A Green; Ian Poulton; Teresa Lambe; Adrian V S Hill; Katie J Ewer; Alexander D Douglas
Journal:  EBioMedicine       Date:  2022-10-06       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.